Oncotelic Awarded BARDA Funding for Development of OT-101 for long COVID
Oncotelic Therapeutics, Inc through its wholly owned subsidiary Oncotelic Inc., a developer of treatments for rare and orphan indications, including Parkinson's Disease, PDAC, DIPG, and…
Read More...
Read More...
